Investors

Financial Overview

CLINUVEL has raised over A$95million since 2006 to fund its clinical program for afamelanotide. Some figures may vary slightly to CLINUVEL's reporting due to rounding, please consult our Announcements for formal financial releases.

Latest Quarterly Report (Appendix 4C)

Latest Quarterly Report (Appendix 4C)Q1 2016 - Calendar year
Cash and financial assets at end of Quarter A$19.55 million
Average net operating cash burn (2016) A$0.75 million per month

Operating Cash Outflows and Assets - Last 5 Years

Calendar QuarterQuarterly Operating Cash OutflowsCash & Financial Assets at Hand
Q1 12 2.58 9.289
Q2 12 2.03 13.173
Q3 12 1.86 11.453
Q4 12 2.29 10.110
Q1 13 2.55 7.920
Q2 13 2.24 12.569
Q3 13 2.49 11.138
Q4 13 2.07 9.748
Q1 14 2.02 8.481
Q2 14 1.74 14.626
Q3 14 2.32 13.042
Q4 14 1.91 11.980
Q1 15 1.81 11.388
Q2 15 1.75 10.573
Q3 15 2.43 9.582
Q4 15 2.56 7.499
Q1 16 2.47 14.170
Q2 16 0.73 13.845
Q3 16 -3.40 17.265
Q4 16   19.550

All figures rounded to AUD$m. 


financial overview 2.jpg

Balance Sheet, Profit, Loss and Cash Flow

  June
2016
June
2015
June 2014 June 2013 June 2012 June 2011 June 2010 June 2009 June 2008 June 2007 June 2006
Balance Sheet                      
   Cash and financial assets at end of Quarter 13.8 10.6 14.6 12.6 13.17 17.5 27.0 37.8 50.8 62.3 10.6
   Total Assets 20.1 13.6 17.2 15.8 16.0 20.2 29.5 41.6 55.0 67.8 17.0
   Total Liabilities 2.3 2.4 1.7 2.0 2.4 3.8 3.1 4.5 3.1 2.4 3.1
   Total Equity 17.8  11.2 15.4 13.8 13.6 16.4 26.4 37.1 51.8 65.4 14.0
P and L Statement                      
   Net Profit (Loss) (3.2) (10.4) (5.5) (6.8) (9.8) (11.4) (11.5) (15.4) (14.7) (9.2) (10.8)
Cash Flow Statement                      
   Net Cash provided by (Used in) Operating activities (5.0)  (4.5) (4.8) (6.3) (10.0) (9.5) (11.8) (11.0) (7.2) (8.2) (11.4)
Sales reimbursements 3.6  2.9 2.2 1.55 0.86 0.17 - - - - -

All figures rounded to AUD$m.

End of Financial Year

End of Financial Year June 30
Full Year Results Released By no later than August 31
Q1 Results Released (Appendix 4C) By no later than April 30
Q2 Results Released (Appendix 4C) By no later than July 31
Q3 Results Released (Appendix 4C) By no later than October 31
Q4 Results Released (Appendix 4C) By no later than January 31
Half Yearly Report Released (Appendix 4D) By no later than February 28

Capital Raisings

Capital Raisings (since Jan '06)$m Raised# Shares (m)*Price*
May 2006 Placement $ 5.0 1.5 $3.41
Sep 2006 Rights Issue and Placement $ 35.2 9.1 $3.85
Apr 2007 Placement $ 26.0 2.4 $10.70
Jun 2012 Placement $6.0 3.4 $1.75
May 2013 Placement $6.3 2.98 $2.136
Jun 2014 Placement $7.2 4.17 $1.658
Mar 2016 Placement $8.3 2.53 $3.30

* Represented at post-consolidated basis after capital re-organisation November 2010 (10:1 Reverse Stock Split).

Last updated 31 January 2017

Quick Links